Results 141 to 150 of about 22,351 (243)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis

, 2011
Clemens Warnke1,2, Olaf Stüve3,4, Hans-Peter Hartung1, Anna Fogdell-Hahn2, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany; 2Department of Clinical Neuroscience, Karolinska Institute, Stockholm,
Hartung HP, Fogdell-Hahn A, Kieseier B, Warnke C, Stüve O   +4 more
core  

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study

European Journal of Neurology, Volume 33, Issue 6, June 2026.
Siponimod lowered the risk of wheelchair use in SPMS patients compared to placebo, especially in those with active disease. Time to wheelchair is a key metric for evaluating treatment in SPMS. ABSTRACT Background Delaying time to requiring a wheelchair in people living with MS is an important treatment goal to maintain quality of life and guard against
Patrick Vermersch, Sophie Arnould, Ralf Gold, Ludwig Kappos, Robert Fox, Amit Bar‐Or, Bruce A. C. Cree, Soudeh Ansari, Daniela Piani Meier, Goeril Karlsson, Nicolas Rouyrre, Gavin Giovannoni   +11 more
wiley   +1 more source

Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod

, 2020
Fingolimod has been the first approved oral medication in MS for its relapsing remitting type. It is a non-selective sphingosine1-phosphate (S1P) receptor modulator on lymphocytes. Engagement of this receptor blocks the T cells and B cells migration from
Harirchian, M.H., Sadeghipour, A., Poursadeghfard, M., Kamali, H., Sarraf, P.   +4 more
core  

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

Therapeutic Advances in Neurological Disorders, 2016
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing.
Bhupendra O. Khatri
doaj   +1 more source

Effects of Crocin on Brain Neurotrophins, Cognition, Balance and Pain in Toxic-Induced Demyelination Model

Acta Neurologica Taiwanica
Objective: The purpose of this study was to investigate the effects of Crocin on brain neuroterophins, cognition, sensory and motor dysfunction and compare to fingolimod effects in toxic-induced demyelination with Ethidium Bromide (EB) in female Wistar ...
Rouholah Fatemi, Hadi Fathi Moghaddam, Yaghoub Farbod, Roya Bigtashkhani   +3 more
doaj   +1 more source

Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series

Therapeutic Advances in Neurological Disorders
An expansion in the availability of generic specialty disease modifying therapies (DMTs) for treatment of multiple sclerosis (MS) has increased recently.
Darin T. Okuda, Lauren M. Tardo, Crystal M. Wright, Shanan B. Munoz, Tom G. Punnen, Mahi A. Patel, Tatum M. Moog, Katy W. Burgess   +7 more
doaj   +1 more source

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

New England Journal of Medicine, 2010
L. Kappos, E. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, Lixin Zhang-Auberson, P. Burtin   +10 more
semanticscholar   +1 more source

Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury

Qi Shi,1,* Tingting Hu,2,* Lixia Xu,2,* Jiayuanyuan Fu,1 Yehong Fang,1 Yu Lan,1 Weijia Fan,2 Qiaoli Wu,2 Xiaoguang Tong,1– 3 Hua Yan1– 3 1Clinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Medical University, Tianjin,
Xu L, Fang Y, Fan W, Hu T, Wu Q, Shi Q, Fu J, Tong X, Yan H, Lan Y   +9 more
core  

Acute onset of fingolimod-associated macular edema

, 2016
PurposeFingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs ...
Quan Dong Nguyen, Mohamed Kamel Soliman, Zabad, Rana K., Nguyen, Quan Dong, Jack, Loren, Neil Jouvenat, Sadiq, Mohammad A., Soliman, Mohamed Kamel, Mohammad A. Sadiq, Loren Jack, Sarwar, Salman, Kedar, Sachin, Salman Sarwar, Jouvenat, Neil, Sachin Kedar, Rana K. Zabad   +15 more
core   +1 more source

Therapeutic Potential of Fingolimod in Diabetes Mellitus and Its Chronic Complications

Jie Li,1,2 Xinyu Nan,1 Yixuan Ma,3 Zhen Wang,4 Hui Fang1,2 1Department of Internal Medicine, Hebei Medical University, Shijiazhuang, 050000, People’s Republic of China; 2Department of Endocrinology, Tangshan Gongren Hospital, Tangshan, 063000, People’s ...
Fang H, Li J, Ma Y, Nan X, Wang Z
core